Aptevo ((APVO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aptevo Therapeutics is conducting a pivotal clinical study titled ‘A Phase 1b/2 Open-Label Study of APVO436 in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).’ The study aims to evaluate the safety and efficacy of the combination treatment in adult patients with newly diagnosed, CD123+ AML, a significant step in finding effective therapies for this aggressive cancer.
The study tests an experimental treatment combining APVO436, an infusion drug, with Venetoclax and Azacitidine. Venetoclax is administered orally, while Azacitidine is given intravenously, both following a 28-day cycle. This combination targets the leukemia cells, aiming to improve patient outcomes.
The study follows an open-label, single-group design, focusing on treatment as its primary purpose. There is no masking involved, allowing researchers to directly observe the effects of the treatment combination.
Key dates for the study include its start on October 4, 2024, with the latest update submitted on May 9, 2025. These dates mark the study’s progression and ongoing data collection, crucial for timely results and analysis.
This study update could positively influence Aptevo’s stock performance, as successful results may enhance investor confidence and position the company as a leader in AML treatment innovation. Competitors in the AML treatment space will be closely watching these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.